Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Part D Protected Classes: Manufacturers, Payers Agree On Need For Specifics

Executive Summary

Both levels of review for determining protected classes under Medicare Part D could stand to have more specific guidelines on the selection of participants and on what drug information is to be considered, manufacturers and payers told CMS in comments

You may also be interested in...



Protected Class Lobbying Begins: Bayer Seeks Protection For MS Therapy

Bayer Healthcare is asking CMS to expand Medicare Part D protected class status to immunomodulators used to treat multiple sclerosis

Protected Class Lobbying Begins: Bayer Seeks Protection For MS Therapy

Bayer Healthcare is asking CMS to expand Medicare Part D protected class status to immunomodulators used to treat multiple sclerosis

CMS Opens Way To Add, Or Subtract, Protected Classes In Part D Formularies

CMS is creating a multi-step process that will give outside experts and the public a role in adding or subtracting "protected" drug classes in Medicare Part D, as well as making exceptions to the rule that all drugs must be covered in a protected class

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel